Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy

被引:147
作者
Mirlekar, Bhalchandra [1 ]
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA
关键词
Immune-suppressive cytokines; tumor microenvironment; cancer immunotherapy; antitumor immunity; tumor growth; GROWTH-FACTOR-BETA; REGULATORY T-CELLS; HUMAN MONOCLONAL-ANTIBODY; BREAST-CANCER; IL-4-PSEUDOMONAS EXOTOXIN; CLINICAL DEVELOPMENT; CYTOKINE EXPRESSION; INTERLEUKIN-4; IL-4; ANTITUMOR IMMUNITY; SUPPRESSOR-CELLS;
D O I
10.1177/20503121211069012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines play a critical role in regulating host immune response toward cancer and determining the overall fate of tumorigenesis. The tumor microenvironment is dominated mainly by immune-suppressive cytokines that control effector antitumor immunity and promote survival and the proliferation of cancer cells, which ultimately leads to enhanced tumor growth. In addition to tumor cells, the heterogeneous immune cells present within the tumor milieu are the significant source of immune-suppressive cytokines. These cytokines are classified into a broad range; however, in most tumor types, the interleukin-10, transforming growth factor-beta, interleukin-4, and interleukin-35 are consistently reported as immune-suppressive cytokines that help tumor growth and metastasis. The most emerging concern in cancer treatment is hijacking and restraining the activity of antitumor immune cells in the tumor niche due to a highly immune-suppressive environment. This review summarizes the role and precise functions of interleukin-10, transforming growth factor-0, interleukin-4, and interleukin-35 in modulating tumor immune contexture and its implication in developing effective immune-therapeutic approaches. Concise conclusion Recent effort geared toward developing novel immune-therapeutic approaches faces significant challenges due to sustained mutations in tumor cells and a highly immune-suppressive microenvironment present within the tumor milieu. The cytokines play a crucial role in developing an immune-suppressive environment that ultimately dictates the fate of tumorigenesis. This review critically covers the novel aspects of predominant immune-suppressive cytokines such as interleukin-10, transforming growth factor-beta, interleukin-4, and interleukin-35 in dictating the fate of tumorigenesis and how targeting these cytokines can help the development of better immune-therapeutic drug regimens for the treatment of cancer.
引用
收藏
页数:15
相关论文
共 182 条
[1]   Human natural killer cells exposed to IL-2, IL-125 IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells [J].
Agaugue, Sophie ;
Marcenaro, Emanuela ;
Ferranti, Bruna ;
Moretta, Lorenzo ;
Moretta, Alessandro .
BLOOD, 2008, 112 (05) :1776-1783
[2]   PHASE 1 EVALUATION OF BINTRAFUSP ALFA (M7824), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF-β AND PD-L1, IN CERVICAL CANCER [J].
Allan, S. ;
Braiteh, F. ;
Calvo Aller, E. ;
Cervantes, A. ;
Edenfield, W. ;
Li, T. ;
Rasschaert, M. ;
Park-Simon, T-W ;
Longo, F. ;
Paz-Ares, L. ;
Spira, A. ;
Strauss, J. ;
Ojalvo, L. S. ;
Helwig, C. ;
Dussault, I. ;
Gulley, J. L. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 :A72-A73
[3]   IFN-γ Inhibits IL-4-Induced Type 2 Cytokine Expression by CD8 T Cells In Vivo and Modulates the Anti-Tumor Response [J].
Apte, Simon H. ;
Groves, Penny ;
Olver, Stuart ;
Baz, Adriana ;
Doolan, Denise L. ;
Kelso, Anne ;
Kienzle, Norbert .
JOURNAL OF IMMUNOLOGY, 2010, 185 (02) :998-1004
[4]   Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics [J].
Autio, Karen ;
Oft, Martin .
CURRENT ONCOLOGY REPORTS, 2019, 21 (02)
[5]   Resistance to Checkpoint Inhibition in Cancer Immunotherapy [J].
Barrueto, Luisa ;
Caminero, Francheska ;
Cash, Lindsay ;
Makris, Courtney ;
Lamichhane, Purushottam ;
Deshmukh, Rahul R. .
TRANSLATIONAL ONCOLOGY, 2020, 13 (03)
[6]   Transforming Growth Factor-β Signaling in Immunity and Cancer [J].
Batlle, Eduard ;
Massague, Joan .
IMMUNITY, 2019, 50 (04) :924-940
[7]   Epigenetic Determinants of Cancer [J].
Baylin, Stephen B. ;
Jones, Peter A. .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2016, 8 (09)
[8]   Cytokines in clinical cancer immunotherapy [J].
Berraondo, Pedro ;
Sanmamed, Miguel F. ;
Ochoa, Maria C. ;
Etxeberria, Inaki ;
Aznar, Maria A. ;
Luis Perez-Gracia, Jose ;
Rodriguez-Ruiz, Maria E. ;
Ponz-Sarvise, Mariano ;
Castanon, Eduardo ;
Melero, Ignacio .
BRITISH JOURNAL OF CANCER, 2019, 120 (01) :6-15
[9]   Cold Tumors: A Therapeutic Challenge for Immunotherapy [J].
Bonaventura, Paola ;
Shekarian, Tala ;
Alcazer, Vincent ;
Valladeau-Guilemond, Jenny ;
Valsesia-Wittmann, Sandrine ;
Amigorena, Sebastian ;
Caux, Christophe ;
Depil, Stephane .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[10]   Tumor-induced perturbations of cytokines and immune cell networks [J].
Burkholder, Brett ;
Huang, Ren-Yu ;
Burgess, Rob ;
Luo, Shuhong ;
Jones, Valerie Sloane ;
Zhang, Wenji ;
Lv, Zhi-Qiang ;
Gao, Chang-Yu ;
Wang, Bao-Ling ;
Zhang, Yu-Ming ;
Huang, Ruo-Pan .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2014, 1845 (02) :182-201